Calidi Biotherapeutics, Inc. Common Stock (CLDI)
0.2435
-0.0023 (-0.94%)
NYSE · Last Trade: Jul 7th, 2:58 PM EDT
Detailed Quote
| Previous Close | 0.2458 |
|---|---|
| Open | 0.2540 |
| Bid | 0.2435 |
| Ask | 0.2491 |
| Day's Range | 0.2249 - 0.2600 |
| 52 Week Range | 0.2027 - 3.890 |
| Volume | 1,324,181 |
| Market Cap | 7.74M |
| PE Ratio (TTM) | -0.1467 |
| EPS (TTM) | -1.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,708,057 |
Chart
News & Press Releases
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
NetworkNewsWire Editorial Coverage : An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) ( Profile ) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON) , Roche (OTCQX: RHHBY) and…
Via Investor Brand Network · July 7, 2025
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END
Via FinancialNewsMedia · July 7, 2025
Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy
While studying why non-human primates aren’t as likely to suffer from certain cancers when compared to humans, UC Davis scientists discovered a genetic mutation that could explain this anomaly. Their findings were published in the Nature Communications journal. This discovery could open the door to the development of more powerful treatments for cancer.
Via Investor Brand Network · July 3, 2025
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its RedTail platform—a systemically delivered virotherapy designed to target metastatic cancers and deliver genetic payloads. Preclinical data presented at AACR and ASCO showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and IND-enabling studies for lead candidate CLD-401, with a filing expected by end of 2026. Calidi also opened an IND for its intratumoral virotherapy, CLD-201, with Phase I trials anticipated by year-end. The company ended Q1 with $10.6 million in cash and a significantly reduced burn rate, aiming to rapidly advance its pipeline while enhancing shareholder value.
Via Investor Brand Network · June 27, 2025
Could Wheat Germ Hold the Key to Supercharging Immunotherapy? New Research Hopes to Find Out
An ongoing clinical trial at the Comprehensive Cancer Center at UC Davis seeks to find out whether fermented wheat germ could help cancer patients undergoing immunotherapy have better outcomes and live full lives, or even beat cancer.
Via Investor Brand Network · June 24, 2025
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · June 23, 2025
Study Explains Why Most Smokers Never Get to Develop Lung Cancer
Newly published research has uncovered why most smokers don’t develop lung cancer even after years or even decades of consuming tobacco. Even though tobacco is one of the main causes of lung cancer, containing various chemicals that can trigger the disease by damaging DNA, only a small number of smokers actually develop the deadly condition. According to researchers, some cigarette smokers seem to possess certain defense systems that prevent them from developing lung cancer even as they continue to expose themselves to tobacco.
Via Investor Brand Network · June 23, 2025
Via Benzinga · June 13, 2025
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth
Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move to harness experienced leadership for the company’s next phase of growth. His extensive background in oncology, successful track record in fundraising and strategic partnerships, and comprehensive understanding of the biotech landscape position him to effectively steer Calidi’s innovative therapies through clinical development and toward commercialization.”
Via Investor Brand Network · June 10, 2025
Celebrity Announcements of Breast Cancer Underscore Increasing Prevalence in Younger Women
Many young celebrities have recently announced that they have been diagnosed with breast cancer . This is a clear pointer to the public that cases of this disease among younger women not yet 50 years of age are rising in America.
Via Investor Brand Network · June 10, 2025
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Unveils Promising Data on CLD-401 at ASCO 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads. The company unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. The announcement reads, “Calidi has previously demonstrated its pioneering efforts in developing an enveloped form of its proprietary oncolytic virus that is significantly more resistant to immune clearance than non-enveloped forms, allowing for systemic delivery and efficacy in syngeneic tumor-bearing pre-clinical models. Calidi has further advanced this technology with CLD-401, its first therapeutic candidate from the RedTail platform. New data presented at the meeting demonstrate a novel genetic modification in which a chimeric CD55 receptor is incorporated into the envelope shielding the virus. Because CD55 receptor expression acts as a robust inhibitor of complement, this modification further enhances the virus’s resistance to rapid clearance by the humoral immune system following intravenous administration.”
Via Investor Brand Network · June 5, 2025
Via Benzinga · June 3, 2025
Korean Researchers Develop AI to Predict Cancer Patients’ Response to Immunotherapy
A research team whose leadership is based in South Korea has developed an AI model for predicting how cancer patients will respond to immunotherapy. Designed to improve the precision of treatment in colorectal and gastric cancer, the AI model could provide physicians with a significantly more accurate tool for customizing therapies.
Via Investor Brand Network · June 2, 2025
University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy
Texas’ Cancer Prevention & Research Institute has awarded $3 million to the University of Houston to establish a biomarker core for cancer immunotherapy. The research institute has earned a reputation for funding research projects which are groundbreaking. The $3m is a fraction of its $93m total package earmarked for awarding grants to entities within the state.
Via Investor Brand Network · May 29, 2025
BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy
Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy hold the promise of offering new hope to cancer patients, addressing the limitations of existing treatments, and potentially improving survival rates across multiple cancer types. The company’s ongoing research and deep commitment to scientific excellence position it at the forefront of next-generation cancer care.
Via Investor Brand Network · May 22, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO
Effective leadership is a cornerstone of organizational success, particularly in the dynamic and high-stakes realm of biotechnology. Recognizing the pivotal role of seasoned leadership, Calidi Biotherapeutics (NYSE American: CLDI) has announced the appointment of Eric Poma, PhD, as its new Chief Executive Officer and member of the board of directors ( https://ibn.fm/qMEu4 ). This strategic transition underscores Calidi’s commitment to advancing its innovative cancer therapies under experienced guidance. Dr. Poma succeeds Allan Camaisa, who will continue to serve as a board member.
Via Investor Brand Network · May 19, 2025
New Multimodal AI System Boosts the Accuracy of Lung Cancer Screening
Early diagnosis of lung cancer is pivotal to effective treatment because this disease is very challenging to treat. Advances in AI are transforming the screening for this disease, improving both efficiency and accuracy. Existing screening methods such as low-dose CT have several challenges. These include high rates of false-positives and a high variability when reporting other incidental but critical information, such as findings on cardiovascular diseases.
Via Investor Brand Network · May 16, 2025
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses
Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR showcasing IL15 superagonist delivery via engineered oncolytic virus. Calidi also announced key leadership additions, including CEO Dr. Eric Poma and CMO Dr. Guy Clifton, as it advances systemic virotherapies targeting metastatic cancers.
Via Investor Brand Network · May 15, 2025
Getting a Second Opinion After Breast Cancer Diagnosis Doesn’t Delay Treatment Commencement
It is very natural to feel immense anxiety and fear after receiving a breast cancer diagnosis. Most people don’t consider seeking second opinions and would rather begin treatment right away. After all, breast cancer is one of the deadliest types of cancer in women, second only to lung cancer in terms of fatalities. The Breast Cancer Research Foundation estimates that slightly over 42,000 women will die from the condition in 2025, making it one of the most prolific killers in the USA.
Via Investor Brand Network · May 12, 2025
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment
Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation.
Via Investor Brand Network · May 9, 2025
Study: Women with Lung Cancer Have Worse Outcomes Due to Genes Linked to Pregnancy
According to a study conducted recently at Memorial Sloan Kettering (MSK) Cancer Center, lung cancer co-opts some genes usually involved in helping fetuses to grow. The lung cancer leverages these genes to evade the immune system of the patient. The researchers found that because of this, women in whom these genes were activated tended to have poorer outcomes.
Via Investor Brand Network · May 6, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research
Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by 2050 ( https://ibn.fm/VfZlY ). These numbers underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.
Via Investor Brand Network · April 30, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research
Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE American: CLDI) announcement of promising preclinical results for its systemic RTNova platform, highlighting the critical role of research in combating cancer.
Via Investor Brand Network · April 29, 2025
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload
Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first therapeutic payload for its systemic antitumor virotherapy platform, RTNova. Preclinical data presented at the AACR Annual Meeting show that Calidi’s engineered vaccinia virus can deliver IL15 superagonist directly into the tumor microenvironment, significantly boosting immune response and tumor elimination while minimizing systemic toxicity. The RTNova platform aims to treat metastatic cancers by enabling systemic delivery of tumor-targeted virotherapies.
Via Investor Brand Network · April 28, 2025
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Grants Inducement Stock Option to New CEO Eric Poma
Calidi Biotherapeutics (NYSE American: CLDI) a clinical-stage biotechnology company advancing targeted antitumor virotherapies, announced the approval of an inducement non-qualified stock option grant to new Chief Executive Officer Eric Poma, Ph.D. The grant includes the option to purchase 726,412 shares at an exercise price of $0.469, the closing price of Calidi’s common stock on April 22, 2025. The options will vest over four years, with 25% vesting on April 22, 2026, and the remainder vesting in equal monthly installments through April 22, 2029, in accordance with Section 711 of the NYSE American LLC Company Guide.
Via Investor Brand Network · April 25, 2025